While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel supplying blood to the brain is obstructed), bleeding or thromboembolism (a condition that happens when a blood clot forms elsewhere in the body and travels through the blood stream to plug another vessel), limited data are available on the number of NVAF patients and the reasons why NVAF patients in Italy stop or change their treatment with blood thinners to prevent stroke or thromboembolism. By following the NVAF patients in routine clinical practice in Italy who are treated with rivaroxaban to prevent stroke or systemic embolism researchers want to find out how many NVAF patients and for what reasons NVAF patients stopped or changed rivaroxaban treatment. Study data will be collected through patients' routine visits at their treating doctor over a period of 24 months for each patient.
Study Type
OBSERVATIONAL
Enrollment
812
Treatment dose is following the description of physicians.
Many locations
Multiple Locations, Italy
Date of start of rivaroxaban treatment
Time frame: 24 months
Date of stop of rivaroxaban treatment
Time frame: 24 months
Number of patients who discontinue (i.e: number of discontinuation) from study initiation to end of observation/follow up.
Time frame: 24 months
Reasons for discontinuation of rivaroxaban therapy
* therapy discontinuation due to adverse event (AE) * therapy discontinuation for non AE related reason * physician decision * patient lost to follow up, no remote contact * patient decision (not related to AE) * patient is in stable sinus rhythm * patient decided to terminate study participation but agreed to further use of data collected so far. * patient decided to terminate study participation and refused further use of collected data. * Patient died * Treatment switch
Time frame: 24 months
Reason for dose change of rivaroxaban therapy
* Change in Creatinine Clearance (CrCL) * Insufficient therapeutic effect * Adverse event
Time frame: 24 months
Reason for switch to other therapy
* Ischemic event * Bleeding and site of bleeding * Adverse drug reaction * Drug interaction with other therapies * New treatment after switch
Time frame: 24 months
Treatment adherence: Self-reported medication adherence measured by the MMAS-8 (Morinsky Scale score)
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.